Skip to main content
. Author manuscript; available in PMC: 2015 Mar 9.
Published in final edited form as: Biol Blood Marrow Transplant. 2010 Jan 29;16(4):555–559. doi: 10.1016/j.bbmt.2009.12.004

Table 2.

Transplant Characteristics

Number
Donor
    MSD 8
    MUD 4
    1 antigen mismatched related 2
Cell type
    G-CSF mobilized peripheral blood stem cells 10
    Bone marrow 4
Conditioning
    Reduced-intensity (Melphalan-based)
        Melphalan 140 mg/m2 + fludarabine 120 mg/m2 + Gemtuzumab (2, 4, 6, 9 or 16 mg/m2) 8
        Melphalan 100 mg/m2 + fludarabine 120 mg/m2 1
    Myeloablative (Busulfan-based)
        i.v. Busulfan 520 mg/m2 + fludarabine 160 mg/m2 3
        i.v. Busulfan 520 mg/m2 + clofarabine 120 mg/m2 + fludarabine 40 mg/m2 1
        p.o. Busulfan 1 mg/kg × 10 doses + cyclophosphamide 120 mg/kg + thiotepa 750 mg/m2 1
GVHD prophylaxis
    Tacrolimus + methotrexate 13
    Cyclosporine + methotrexate 1

MSD indicates matched sibling donor; MUD, matched unrelated donor; i.v., intravenous; p.o., oral; GVHD, graft-versus-host disease; G-CSF, granulocyte colony-stimulating factor.